Accuracy of a Continuous Glucose Monitor in the Intensive Care Unit.

IF 7.4 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Diabetes technology & therapeutics Pub Date : 2026-09-01 Epub Date: 2026-02-11 DOI:10.1177/15209156261423933
Eric Cucchi, Asem Ali, Yurima Guilarte-Walker, Bruce Barton, Samir Malkani, John Mordes
{"title":"Accuracy of a Continuous Glucose Monitor in the Intensive Care Unit.","authors":"Eric Cucchi, Asem Ali, Yurima Guilarte-Walker, Bruce Barton, Samir Malkani, John Mordes","doi":"10.1177/15209156261423933","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Continuous glucose monitoring (CGM) devices are routinely used in the outpatient management of diabetes. They are not yet approved for use in intensive care units (ICUs). The main objective of this study was to determine the accuracy of CGM glucose determinations made in an ICU by comparing them with standard glucose measurements obtained during routine care. Secondary objectives were to determine the frequency of device malfunctions or adverse events and to assess acceptance of CGM use by caregivers.</p><p><strong>Methods: </strong>Dexcom™ G7 CGM sensors were placed on non-randomized, consented ICU patients with known hyperglycemia. CGM glucose concentrations were recorded in a Dexcom Clarity™ database and compared with near-simultaneous (±5 min) measurements obtained by laboratory or point-of-care measurements recorded in an electronic medical record. Determinations of accuracy were made using a Clarke Error Grid plot and by calculating mean absolute relative difference (MARD). Device failure and adverse event data were recorded in the electronic record. Caregiver acceptance was assessed by interview.</p><p><strong>Results: </strong>During a 9-month period, 16 subjects were enrolled after obtaining informed consent. The median duration of CGM use on subjects was 5.5 (range 1-20) days. A total of 941 near-simultaneous CGM and routine care data were collected. Clarke Error Grid comparison of CGM and routine care data showed 99.7% of readings in regions A or B and 0.3% in other regions. The MARD of all readings was 12.25%. There were no adverse events attributable to the CGM recorded. Qualitative analysis of nursing responses revealed no concerns regarding the addition of CGM to the routine workflow.</p><p><strong>Conclusion: </strong>CGM glucose readings in the ICU may be reliable to use in certain critically ill patient populations. CGM may not be reliable in patients requiring high-dose vasopressors. The use of CGM to enhance patient care in ICUs merits additional research.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":"916-923"},"PeriodicalIF":7.4000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes technology & therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/15209156261423933","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/2/11 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: Continuous glucose monitoring (CGM) devices are routinely used in the outpatient management of diabetes. They are not yet approved for use in intensive care units (ICUs). The main objective of this study was to determine the accuracy of CGM glucose determinations made in an ICU by comparing them with standard glucose measurements obtained during routine care. Secondary objectives were to determine the frequency of device malfunctions or adverse events and to assess acceptance of CGM use by caregivers.

Methods: Dexcom™ G7 CGM sensors were placed on non-randomized, consented ICU patients with known hyperglycemia. CGM glucose concentrations were recorded in a Dexcom Clarity™ database and compared with near-simultaneous (±5 min) measurements obtained by laboratory or point-of-care measurements recorded in an electronic medical record. Determinations of accuracy were made using a Clarke Error Grid plot and by calculating mean absolute relative difference (MARD). Device failure and adverse event data were recorded in the electronic record. Caregiver acceptance was assessed by interview.

Results: During a 9-month period, 16 subjects were enrolled after obtaining informed consent. The median duration of CGM use on subjects was 5.5 (range 1-20) days. A total of 941 near-simultaneous CGM and routine care data were collected. Clarke Error Grid comparison of CGM and routine care data showed 99.7% of readings in regions A or B and 0.3% in other regions. The MARD of all readings was 12.25%. There were no adverse events attributable to the CGM recorded. Qualitative analysis of nursing responses revealed no concerns regarding the addition of CGM to the routine workflow.

Conclusion: CGM glucose readings in the ICU may be reliable to use in certain critically ill patient populations. CGM may not be reliable in patients requiring high-dose vasopressors. The use of CGM to enhance patient care in ICUs merits additional research.

重症监护病房连续血糖监测仪的准确性。
目的:连续血糖监测(CGM)设备常规用于糖尿病的门诊管理。它们尚未被批准用于重症监护病房(icu)。本研究的主要目的是通过与常规护理中获得的标准血糖测量值进行比较,确定在ICU中进行的CGM血糖测定的准确性。次要目的是确定器械故障或不良事件的频率,并评估护理人员对CGM使用的接受程度。方法:Dexcom™G7 CGM传感器放置在已知高血糖的非随机、同意的ICU患者身上。将CGM葡萄糖浓度记录在Dexcom Clarity™数据库中,并与实验室或电子病历中记录的护理点测量值获得的近同时(±5分钟)测量值进行比较。通过克拉克误差网格图和计算平均绝对相对差(MARD)来确定精度。器械故障和不良事件数据记录在电子记录中。通过访谈评估照顾者的接受程度。结果:在9个月的时间里,16名受试者在获得知情同意后入组。受试者使用CGM的中位持续时间为5.5天(范围1-20天)。总共收集了941例几乎同时进行的CGM和常规护理数据。克拉克误差网格比较CGM和常规护理数据显示,99.7%的读数在A区或B区,0.3%在其他地区。所有读数的MARD为12.25%。没有记录到可归因于CGM的不良事件。对护理反应的定性分析显示,在常规工作流程中加入CGM没有任何问题。结论:ICU的CGM血糖读数在某些危重患者群体中可能是可靠的。对于需要大剂量血管加压药物的患者,CGM可能不可靠。使用CGM来加强icu患者护理值得进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Diabetes technology & therapeutics
Diabetes technology & therapeutics 医学-内分泌学与代谢
CiteScore
10.60
自引率
14.80%
发文量
145
审稿时长
3-8 weeks
期刊介绍: Diabetes Technology & Therapeutics is the only peer-reviewed journal providing healthcare professionals with information on new devices, drugs, drug delivery systems, and software for managing patients with diabetes. This leading international journal delivers practical information and comprehensive coverage of cutting-edge technologies and therapeutics in the field, and each issue highlights new pharmacological and device developments to optimize patient care.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书